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Abstract: Background: Pain after breast cancer surgery remains largely unexplained and inconsistently
quantified. This study aims to describe the perioperative pain patterns in patients with breast cancer,
up to two years after surgery. Methods: This is a pre-planned sub-study of the Ketorolac in Breast
Cancer (KBC) trial. The KBC trial was a multicentre, prospective, double-blind, placebo-controlled,
randomised trial of a single dose of 30 mg of ketorolac just before breast cancer surgery, aiming to
test its effect on recurrences. This sub-study focuses only on pain outcomes. From 2013 to 2015,
203 patients were randomised to ketorolac (n = 96) or placebo (n = 107). Structured questionnaires
were delivered by telephone after one and two years, exploring the presence, location, permanence,
and frequency of pain. Patients’ perceptions of pain were captured by an open-ended question,
the responses to which were coded and classified using hierarchical clustering. Results: There was no
difference in pain between the ketorolac and the placebo group. The reported incidence of permanent
pain was 67% and 45% at one and two years, respectively. The largest category was musculoskeletal
pain. Permanent pain was mainly described in patients with musculoskeletal pain. The description
of pain changed in most patients during the second postoperative year, i.e., moved from one category
to another (no pain, permanent, or non-permanent pain, but also, the localisation). This phenomenon
includes patients without pain at one year. Conclusions: Pain is a complex phenomenon, but also
a fragile and unstable endpoint. Pain after breast cancer surgery does not necessarily mean breast
pain but also musculoskeletal and other pains. The permanence of pain and the pain phenotype can
change over time.
J. Clin. Med. 2020, 9, 3831; doi:10.3390/jcm9123831 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 3831 2 of 12
Keywords: ketorolac; breast cancer; acute pain; chronic pain; musculoskeletal pain
1. Introduction
Pain remains a significant problem after breast cancer surgery. The problem is largely unexplained
and inconsistently quantified [1]. The dynamics of acute and persistent postoperative pain are variably
reported, with mixed results. Even the localisation of the pain is reported variably, leading to a potential
misunderstanding when examining persistent pain after breast cancer surgery.
This may be partly due to the fact that some of the pain syndromes are associated with adjuvant
treatment, such as polyneuropathy (induced by chemotherapy) and musculoskeletal pain (caused
by endocrine therapy), and do not meet the definition of postsurgical pain. However, other pain
syndromes are mostly unexplained, even if they are, at least partially, related to surgery, such as
shoulder pain [2].
From the patient’s perspective, pain after treatment for breast cancer can affect quality of life,
whether or not it is clearly related to the surgical insult. In addition, as the cause of the onset of new
musculoskeletal pain is usually not explained, it would be important to describe postoperative pain
patterns, not only limited to the surgical site, but also in other areas.
This sub-study of the Ketorolac in Breast Cancer (KBC) study aims to describe the perioperative
pain patterns in patients with breast cancer, up to two years after surgery. The KBC trial was a
randomised, placebo-controlled trial designed to test the hypothesis that a single intraoperative dose
of ketorolac may be associated with prolonged disease-free survival after surgery in breast cancer
patients (NCT01806259) [3]. The trial reported no effect on acute postoperative pain from a single
dose of ketorolac. Acute pain was considered a safety outcome, but a sub-study on persistent pain
after surgery was pre-planned. Data were therefore collected prospectively, capturing evidence on
perioperative pain and pain up to two years after surgery.
2. Patients and Methods
2.1. Settings
This is a sub-study of a multicentre, prospective, double-blind, placebo-controlled, randomised
phase III trial of perioperative ketorolac in patients with high-risk breast cancer. Patients were
randomised in a 1:1 ratio to receive either 30 mg of ketorolac tromethamine (Taradyl, N.V. Roche S.A.,
1070 Brussels, Belgium) or placebo before the surgical incision. The present study not only focuses on
comparing pain outcomes between groups, but more broadly describes the characteristics of acute
and persistent pain across the cohort. The study was approved by the institutional review committees
of all the participating centres (central ethics committee: Catholic University of Louvain, EUDRACT
2012-003774-76) and was conducted in accordance with the Declaration of Helsinki and applicable
national and European laws. Patients provided written informed consent. This report is written in
accordance with the CONSORT directives [4].
2.2. Participants
Patients provided written informed consent for the main trial as well as the pain sub-study.
Inclusion criteria included: patients scheduled for curative breast cancer surgery, weighing between 50
and 100 kg, and aged 18 to 75, with a neutrophil-to-lymphocyte ratio > 4 and/or showing evidence of
lymph node invasion and/or triple negative status. Patients were excluded if they refused or could not
follow part of the protocol (preoperative screening, complete treatment, or follow-up), in the case of
history of cancer in the last 2 years, planned non-curative surgery (confirmed preoperative T4 or M1),
and in the presence of a contraindication to ketorolac (or to another drug used in the standardised
anaesthetic protocol).
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2.3. Intervention
General anaesthesia followed a standardised protocol including a continuous infusion of
propofol, ketamine 0.3 mg/kg, clonidine as needed to maintain hemodynamic stability up to 4 µg/kg,
and sufentanil per bolus of 0.1 µg/kg if necessary. Postoperative analgesia included paracetamol as
needed (3 to 4 g/day), tramadol 50 mg, and piritramide 10 mg IM/6h in the case of severe pain.
2.4. Data Collection
Between February 2013 and July 2015, 203 patients from four sites in Belgium were randomised to
ketorolac (n = 96) or placebo (n = 107). Oncological follow-up was carried out by the oncologist in
charge of the patients, initially every 3 months after surgery and then, every 6 months after the second
postoperative year.
In addition, structured questionnaires were delivered by telephone by a research coordinator
(Alain Dekleermaker) after one and two years. These explored the presence of pain, its location,
permanence, frequency, and other characteristics, other sensations and their location, and the presence
of a phantom chest sensation (additional material, Case Report Form—CRF 7 and 16). Musculoskeletal
pain (arthralgia, myalgia, low back pain), neuropathy, headaches, and other types of pain were also
noted. Patient perceptions of pain were captured by an open-ended question, by specifically asking to
“describe the pain” (if the pain was not localised in the initial surgery site/the arm).
2.5. Data Processing and Analyses
2.5.1. Quantitative Analyses
The quantitative analyses have been described previously [3]. In short, the study was designed
to detect a 33% reduction in the risk of recurrence, with a power of 0.8 and an alpha of 0.05.
The intention-to-treat population was used for all efficacy analyses of a possible effect of ketorolac.
Patient demographics, baseline characteristics, and oncology treatments were summarised using
descriptive statistics (mean, standard deviation, median, minimum and maximum values) for
continuous parameters, and frequencies and percentages for categorical data. Group comparisons
were made using the Mann–Whitney, Fisher, or Chi-square test as appropriate, and 95% confidence
intervals were provided where required. All statistical tests were two-sided. For several comparisons,
a Bonferroni correction was used, based on a Type I error of 5%. All data were collected using REDCap
(Research Electronic Data Capture System, Vanderbilt University, Nashville TN 37235, USA) [5,6]
and analysed using SAS statistical software version 9.4 (Copyright, SAS Institute Inc.) and SPSS for
Windows, version 25.0 (IBM Corp. Released 2017, Armonk, NY, USA). The graphs were constructed
using SankeyMATIC (http://sankeymatic.com) and STATISTICA (data analysis software system)
version 7 (StatSoft Inc. 2004, Tulsa, OK, USA).
2.5.2. Thematical/Framework Type Analyses
The open question from the telephone questionnaires was transcribed verbatim and analysed by
Patrice Forget (PF) and Taalke Sitter (TS) as follows:
(1) Identify information about the type of pain, the site and cause, and how it has changed over time.
(2) Organise the codes according to the similar meaning identified in a second and third round
until the saturation is considered reached. The codes were grouped into categories, without any
interpretation concerning a possible aetiology: “permanent pain”, “musculoskeletal pain”, “pain
located in surgical area”, “other located pain”, “polyneuropathy”, and “no pain”. “Permanent
pain” refers to “pain all the time”; “musculoskeletal pain” refers to any pain originating from or
resembling arthralgia, myalgia, or low back pain; “pain located in surgical area” refers to the
patient’s interpretation, primarily related to the pain localisation; “polyneuropathy” refers to
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pain in the extremities associated with positive and/or negative symptoms (like paraesthesia
and numbness).
(3) Classify and group codes in clusters: patients with different types of pain (e.g., with both
polyneuropathy and musculoskeletal pain) were counted in different categories. In contrast,
patients experiencing more than one type of pain within a category were counted once in
that category (e.g., musculoskeletal pain for patients reporting arthralgia and low back pain).
Hierarchical clustering was used to group the different categories, according to the frequency
of their co-occurrence in the individual patient data. Hierarchical clustering has already been
described as useful in pain studies to identify profiles, multiple associations of descriptors,
and combine symptoms into subgroups [7]. The final analysis was expressed by a network plot
using Ward coupling, i.e., showing the clusters with the smallest variance (the most similar) and
a dendrogram (Appendix A).
3. Results
3.1. Patient Characteristics and Quantitative Analyses
Patients had a mean age of 55.7 years (SD 14) ranging from 28 to 85. All were women except
for 1 man from the ketorolac group. All patients received the assigned treatment, and all underwent
surgery after randomisation (Table 1, Figure 1) (adapted from [3]).
Table 1. Baseline characteristics of the patients, tumours, and treatments (adapted from Forget 2019).






Mean (SD) 55.7 (14.0) 56.1 (14.0) 55.4 (13.9)
Range 28–85 30–85 28–85
Gender, n (%)
Female 202 (99%) 95 (99%) 107 (100%)
Male 1 (1%) 1 (1%) 0
Chemotherapy, n (%)
Yes 161 (79%) 80 (83%) 81 (76%)
No 42 (21%) 16 (17%) 26 (24%)
If chemotherapy (anthracyclines with/without taxanes), type (%)
Adjuvant 54 (27%) 27 (28%) 27 (25%)
Neoadjuvant 107 (53%) 53 (55%) 54 (51%)
Type of surgery, n (%)
Mastectomy 119 (59%) 60 (63%) 59 (55%)
Breast-conserving surgery 82 (40%) 34 (35%) 48 (45%)
Missing 2 (1%) 2 (2%) 0
Type of lymphadenectomy, n (%)
None 14 (7%) 6 (6%) 8 (8%)
Sentinel 12 (6%) 5 (5%) 7 (6%)
Complete axillary 176 (87%) 85 (89%) 91 (85%)
Missing 1 (1%) 0 1 (1%)
Post-operative radiotherapy, n (%)
Yes 165 (81%) 77 (80%) 88 (82%)
No 38 (19%) 19 (20%) 19 (18%)
Endocrine therapy, n (%)
Yes 138 (68%) 69 (72%) 69 (64%)
No 64 (31%) 27 (28%) 37 (35%)
Missing 1 (1%) 0 1 (1%)
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Figure 1. Study flow chart. 
No patient was taking strong opioids, and only one patient was taking weak opioids 
preoperatively and stopped after one year. After one year, one patient took weak and one took strong 
opioids. After two years, three patients took weak opioids. 
3.2. Pain Characteristics 
As previously indicated, there was no difference, between the ketorolac and the placebo group, 
in pain on D1 after surgery, neither at rest (p = 0.620) nor in movement (p = 0.254) (Figure 2), even if 
a difference of 3 mg of morphine equivalent appeared (ketorolac group: 5 mg (interquartile range 25–
75: 0–10); placebo group: 8 mg (4–14); p = 0.001) (Table 2). No differences appeared at other time 
points neither for acute pain, nor for chronic pain (Table 2). Changes in pain scores were compared 
between the groups, not revealing any difference. 
Table 2. Preoperative, acute, and persistence postoperative pain. 
Characteristics 
Ketorolac  
(n = 96) 
Placebo  
(n = 107) p-Value 
Preoperative chronic pain 
 13 (14%) 24 (23%) 0.356 
Preoperative pain (any type, including post-biopsy) 
Every day 59 (62%) 62 (58%) 0.583 
One to 3 days a week 0 (0%) 1 (1%)  
Less than once a week 27 (28%) 36 (34%)  
Missing 10 (10%) 8 (8%)  
Acute pain 
Pain at rest at D1 after surgery Verbal simple scale  
(0–4), N (%) 
    0.620 
0 18 (19%) 17 (16%)  
1 35 (37%) 31 (29%)  
2 37 (38%) 47 (44%)  
3 5 (5%) 10 (9%)  
4 1 (1%) 1 (1%)  
Missing 0 (0%) 1 (1%)  
Figure 1. Study flo chart.
o patient was taking strong pioids, an only one patient was taking eak op oids preoperatively
and stopped after one year. After one year, one patient took weak nd one took strong opioids. Afte two
years, three patients took weak opioids.
3.2. Pain Characteristics
As previously indicated, there as no difference, bet een the ketorolac and the placebo group,
in pain on D1 after surgery, neither at rest (p = 0.620) nor in movement (p = 0.254) (Figure 2), even if a
difference of 3 mg of morphine equivalent appeared (ketorolac group: 5 mg (interquartile range 25–75:
0–10); placebo group: 8 mg (4–14); p = 0.001) (Table 2). No differences appeared at other time points
neither for acute pain, nor for chronic pain (Table 2). Changes in pain scores were compared between
the groups, not revealing any difference.
Table 2. Preoperative, acute, and persistence postoperative pain.
Characteristics Ketorolac(n = 96)
Placebo
(n = 107) p-Value
Preoperative chronic pain
13 (14%) 24 (23%) 0.356
Preoperative pain (any type, including post-biopsy)
Every day 59 (62%) 62 (58%) 0.583
One to 3 days a week 0 (0%) 1 (1%)
Less th n once a week 27 (28%) 36 (34%)
Missing 10 (10%) 8 (8%)
Acute pain
Pain at rest at D1 after surgery Verbal simple scale
(0–4), N (%) 0.620
0 18 (19%) 17 (16%)
1 35 (37%) 31 (29%)
2 37 (38%) 47 (44%)
3 5 (5%) 10 (9%)
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Table 2. Cont.
Characteristics Ketorolac(n = 96)
Placebo
(n = 107) p-Value
4 1 (1%) 1 (1%)
Missing 0 (0%) 1 (1%)
Morphine equivalent at D1 (in mg)
Median (interquartile range 25–75) 5 (0–10) 8 (4–14) 0.001
Mean change in pain score to Day 1 (SD) −0.6 (1.16) −0.7 (1.24) 0.357
Mean change in pain score to Day 2 (SD) −0.1 (1.42) 0.1 (1.42) 0.631
Mean change in pain score to Day 3 (SD) 0.7 (1.24) 0.8 (1.27) 0.869
Persistent pain 1 year after surgery
Presence of any type of pain 72 (75%) 70 (65%) 0.137
Average pain score
Mean Visual Analogue Scale (0–10) (SD) 2.6 (1.4) 2.9 (1.4) 0.166
Persistent pain 2 years after surgery
Presence of any type of pain 57 (63%) 62 (59%) 0.541
Average pain score
Mean Visual Analogue Scale (0–10) (SD) 2.4 (1.5) 2.3 (1.7) 0.805
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In terms of persistent pain, most patients described pain after one and two years. Most of them 
(67%) reported permanent pain at one year, but not at 2 years (45%) (Table 2, Figure 3; Figure 4). The 
Figure 2. Acute pain score on a si l erbal scale (0 to 4) at rest (A) and movement (B) after surgery.
p > 0.05 for all the co parisons. Pain scores are expressed as median, interquartile range (25–75),
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In terms of persistent pain, most patients described pain after one and two years. Most of
them (67%) reported permanent pain at one year, but not at 2 years (45%) (Table 2, Figures 3 and 4).
The largest category among patients describing pain was musculoskeletal pain, and the smallest was
pain associated with polyneuropathy (at 1 and 2 years, 23 and 20, with, respectively, 17 and 15 having
received a chemotherapy, p = 0.004 and 0.01, when compared with no chemotherapy). Permanent pain
(pain at all times) was mainly described in patients with musculoskeletal pain at one and two years,
although pain associated with polyneuropathy was mainly permanent during the first year (Table 3,
Figure 3).
Table 3. Localisation and permanence of pain 1 and 2 years after surgery.
Localisation of Pain after 1 Year n Experiencing Permanent Pain (%)
Pain in surgical area 37 21 (58)
Polyneuropathy 23 22 (96)
Musculoskeletal 56 37 (66)
Other 28 17 (61)
None 61 0
Total: 200 patients (with and without pain), 205 reported pain types
Localisation of Pain after 2 Year n Experiencing Permanent Pain (%)
Pain in surgical area 35 18 (51)
Polyneuropathy 20 10 (50)
Musculoskeletal 66 31 (47)
Other 60 27 (45)
None 77 0
Total: 195 patients (with and without pain), 258 reported pain types
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 7 of 12 
 
largest category among patients describing pain was musculoskeletal pain, and the smallest was pain 
associated wi h polyneuropathy (at 1 and 2 years, 23 nd 20, with, r spectively, 17 and 15 having 
received a chemot erap , p = 0.004 and 0.01, when compared with no ch motherapy). Perm ne t 
pain (pain at all times) was mainly described in patients with musculoskeletal ain at one a d two 
ye rs, although pain associate  with polyneuropathy was mainly permanent during the first year 
(Table 3, Figure 3). 
Table 3. Localisation and permanence of pain 1 and 2 years after surgery. 
Localisation of Pain after 1 Year n Experiencing Permanent Pain (%) 
Pain in surgical area 37 21 (58) 
Polyneuropathy 23 22 (96) 
Musculoskeletal 56 37 (66) 
Other 28 17 (61) 
None 61 0 
Total: 200 patients (with and without pain), 205 reported pain types 
Localisation of Pain after 2 year n Experiencing Permanent Pain (%) 
Pain in surgical area 35 18 (51) 
Polyneuropathy 20 10 (50) 
Musculoskeletal 66 31 (47) 
Other 60 27 (45) 
None 77 0 
Total: 195 patients (with and it  ain), 258 reported pain types 
 
Figure 3. Network plot reporting the numbers of patients reporting pain in different categories (size), 
the proportion of reported pain permanence (gradient: black—permanent; white—non-permanent), 
and the frequency of their co-occurrence (lines thickness indicates the closeness of the relationship, 
based on the inverse Ward distance). 
In terms of pain permanence and location, approximately half of the patients moved from one 
category to another between the first and the second year. For example, 39% of patients (37/94) with 
permanent pain also described it as permanent in the second year, while 18% (11/60) of the pain-free 
patients of the first year reported permanent pain during the second year. Only 44% of patients 
(89/203) remained in the same category for the permanence of pain. A similar pattern was observed 
for localisation. In other words, 30% of the patients (11/37) reporting pain in the surgical area after 
one year described it as such after two years. In total, only 48% (98/203) remained in the same category 
(Figures 4 and 5). 
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based on the inverse ard distance).
I ter s f ai er a e ce a l cati , a r i atel alf f t e atie ts e fr e
cate r t a t er et ee t e first a t e sec ear. r exa le, 39 f atie ts (37/94) it
er a e t ai als escri e it as er a e t i t e sec ear, ile 18 (11/60) f t e ai -free
atie ts f t e first ear re rte er a e t ai ri t e sec ear. l 44 f atie ts
(89/203) re ained in the same category for the permanence of pain. A similar pattern was observed for
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localisation. In other words, 30% of the patients (11/37) reporting pain in the surgical area after one
year described it as such after two years. In total, only 48% (98/203) remained in the same category
(Figures 4 and 5).J. Clin. Med. 2020, 9, x FOR PEER REVIEW 8 of 12 
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3.3. Similarities and Differences in Patients with Pain after One and Two Years
No significant difference between patients with and without pain after 1 and after 2 years was
detected with regards to age, BMI, type of surgery, description of preoperative, and acute postoperative
pain (Table 4). Any differences observed after 1 year in terms of age and BMI (both higher) statistically
disappeared after Bonferroni’s correction for the significance of alpha (0.0025).
Table 4. Patients’ characteristics, with and without pain, 1 and 2 years after surgery. No statistically
significant difference after Bonferroni’s correction for multiple comparisons. p-values according to Chi
square tests and Fisher exact tests as appropriate.








n = 76 p
Gender n (%)
Female 139 (99) 60 (100) - 118 (99) 76 (100) -
Male 1 (1) 0 - 1 (1) 0 -






























Preoperative Pain (Yes/No) 28/108 6/52 0.13 23/91 10/65 0.31
Surgery n (%) 0.53 0.50
Mastectomy 84 (60) 32 (53) 67 (56) 46 (61)
Quadrantectomy/Lumpectomy 55 (39) 27 (45) 52 (44) 28 (37)
Bilateral 13 (9) 8 (13) 11 (9) 10 (13)
Axillary lymph node resection n (%) 0.42 0.69
Complete axillary lymph nodes resection 119(85) 54 (90) 104(87) 64 (84)
Sentinel lymph node 8 (6) 4 (7) 6 (5) 6 (8)
None 12 (9) 2 (3) 8 (7) 6 (8)
Hormonotherapy 96 (69) 43 (72) 0.66 47 (41) 37 (49) 0.30
Sensation of phantom breast (%) 1 (1) 0 - 0 0 -
Association with pain (Yes/No) 0/1 0/0 - 0/0 0/0 -
Pain trajectories were explored but did not differ between patients with or without persistent pain
(respectively, median pain score on a simple verbal scale (0 to 4) at movement, 3 days after surgery:
1 (0–1) vs. 0 (0–1); p = 0.61 after 1 year and 0 (0–1) vs. 1 (0–1); p = 0.47 after two years).
4. Discussion
4.1. Summary of the Results
This study shows that a single dose of ketorolac induced no detectable change in terms of
pain scores (even if associated with a modest decrease in opioids at D1 in the ketorolac group:
5 mg (interquartile range 25–75: 0–10); compared to the placebo group: 8 mg (4–14); p = 0.001).
More interestingly, the pain trajectories were explored here, revealing no difference between the groups,
but clearly showing that most patients described a postoperative appearance of pain in areas other than
the surgical site, with musculoskeletal pain being the most important group. The description of pain
changed in most patients during the second postoperative year, i.e., passed from one category to another
(no pain, permanent, or non-permanent pain, but also, the localisation). This phenomenon includes
patients without pain at one year. Persistent pain was therefore more frequently musculoskeletal,
rather than associated with polyneuropathy, although the latter treatment was clearly a risk factor for
permanent pain (p = 0.004 and 0.01 at 1 and 2 years, compared to the absence of chemotherapy). The type
of surgery and other types of adjuvant treatment(s) were not associated with pain outcomes here.
Were these results surprising? For its anticancer effect, a single dose of ketorolac was not
sufficient to induce a difference in terms of oncological results. One suspected reason is that the
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use (of a single dose) may have been too short [3]. This may also be true for the analgesic effect,
as the use of non-steroidal anti-inflammatory drugs (NSAIDs) is generally recommended for the
duration of postoperative pain [8]. This lack of effect from a single dose of ketorolac, except a small
opioid-sparing effect, was thus not very surprising. However, the pain patterns described were not
expected. Gartner et al. have developed one of the most used questionnaires for assessing pain after
surgery for breast cancer and report a 40% incidence of pain in areas other than the surgical site [9],
which is consistent with our results. New research in the field has focused on an intervention to reduce
the incidence of breast (or surgical) pain after breast cancer surgery. In these studies, pain in other parts
of the body has generally not been reported and it remains unclear if questions about pain beyond
the surgical site were used [10–13]. However, musculoskeletal pain, such as shoulder pain, has been
recognised as a significant burden after breast surgery [2].
Taken together, our results and previous ones suggest that the type of surgery might not be
so important in breast cancer surgery with respect to the risk of persistent pain [9,13]. However,
one would have expected to see adjuvant treatments associated with certain types of pain, such as
aromatase inhibitors, with arthralgia, which was not the case here [14]. This study, however, was not
designed for and would clearly lack power and underfitting for the construction of a multivariable
model. These results must therefore be considered as generating hypotheses. Even if only partially
and in a specific dataset, our results challenge the existing theoretical framework proposing that the
persistent pain after breast cancer surgery is mainly located in the operating site and with constant
characteristics over time. In other words, permanent pain after breast surgery may not be (or not
primarily) directly caused by the surgical insult and even related to the surgery. A late onset of
permanent pain has been observed here and it seems that how patients experience permanent pain and
how their experience changes (or is influenced by interfering factors) during the postoperative years is
mostly unknown. Apart from the type of surgery discussed above and adjuvant treatments, this may
be related to the inherent heterogeneity of the patient profile. This opens up a new area of research,
trying to implement better patient-centred approaches, including in research projects. The patients’
perspective on their own goals and what is acceptable and important, in terms of pain and functional
goals, is essential to understanding important areas of research. This is also true for the treatments
and strategies which should be developed, in a more holistic way, because pain clearly cannot be
considered as an isolated phenomenon, in time or in the body. This should make us consider that
the importance of neurophysiological mechanisms in persistent pain is real but not necessarily the
most important, at least in the long term. Thus, the remaining issues need to be considered from a
holistic perspective when focusing on persistent pain. This is also true of the intriguing late onset of
pain in the surgical area, which is possible but difficult to explain. Is this because women who did not
have pain may return earlier to activities that may cause pain later, e.g., starting heavy lifting earlier
in their recovery, which had implications for longer term pain and recovery? This could explain the
lack of relationship observed between the trajectories of acute pain and the occurrence of persistent
pain. Or is it the opposite? One could also argue the need to explore the impact of visibility/size of
the incision and bruising on pain perception in the short and longer term. Late onset pain merits
further study, given the possibilities of preventive interventions, including the potential influence of a
multidisciplinary approach.
4.2. Limitations
These observations should not be overinterpreted. These are limited to one specific dataset, with
its inherent limits in terms of precision and possibly questionable generalisability, given the high
oncological risk profile of the included patients. The risk of type I error linked to the multiplicity
of analyses may have been controlled too conservatively with Bonferroni’s correction, making it
impossible to conclude on the effect of age and BMI on pain a year after surgery. Since a young age is
mainly associated with a higher risk of persistent pain, it would have been unexpected that the patient
without pain, one year after surgery, was significantly younger than the patients describing pain [1].
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Finally, we were unable to confirm the role of endocrine therapy, radiotherapy, and chemotherapy here,
but the study was not designed for this and was underpowered, even if the effect of these treatments can
without any doubt be complicated by the development of pain [14]. In future studies, it is necessary to
integrate other factors that may influence pain during long-term follow-up such as hormonal therapies,
other hormonal symptoms (hot flashes and night sweats, mood swings), lymphedema and extension
of lymph node dissection, concomitant medical conditions (like arthritis and diabetes), psychological
and psychiatric factors, other illnesses, and social factors.
5. Conclusions
Pain is a complex phenomenon, but also a fragile (from a methodological point of view)
and unstable (from a clinical perspective) endpoint. Pain after breast cancer surgery does not
necessarily mean breast pain, and musculoskeletal pain and other pains may represent a heavier
burden. The permanence of pain and the pain phenotype can change dramatically over time.
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